Surrozen's Dual-Action Eye Drug Enters Trials to Tackle Diabetic Vision Loss
SZN-8141 targets both Wnt signaling and VEGF to restore healthy retinal vessels in diabetic macular edema, now entering Phase 1b/2a trials.
Summary
Surrozen has received FDA clearance to begin human trials of SZN-8141, a first-in-class antibody that simultaneously activates Wnt signaling through the Frizzled 4 receptor and blocks VEGF, the molecule that drives abnormal blood vessel growth in diabetic eye disease. The drug is designed as an intravitreal injection — delivered directly into the eye — for diabetic macular edema, a leading cause of vision loss in adults with diabetes. Preclinical studies showed SZN-8141 could stimulate regrowth of normal retinal vessels while suppressing pathological ones. The DUET Phase 1b/2a trial will enroll roughly 60 treatment-naive patients and compare two doses against the established drug Vabysmo over a four-month follow-up. Initial data are expected in the second half of 2027.
Detailed Summary
Diabetic macular edema is one of the most common and damaging complications of long-term diabetes, causing fluid accumulation in the central retina and progressive vision loss in millions of adults worldwide. Current anti-VEGF therapies slow pathological vessel growth but do not restore normal vascular architecture — leaving many patients with persistent disease burden. Surrozen is now moving to address this gap with SZN-8141, a bifunctional antibody that takes a dual approach: it activates the Wnt signaling pathway through the Frizzled 4 receptor while simultaneously blocking VEGF.
The rationale is biologically compelling. Wnt/Frizzled 4 signaling is essential for building and maintaining the blood-retinal barrier. In diabetic eye disease, this pathway is impaired, contributing to vessel leakage and abnormal angiogenesis. By combining Wnt agonism with VEGF blockade, SZN-8141 aims not just to suppress disease but to actively promote vascular repair — a fundamentally different therapeutic goal from existing injections.
Preclinical data the company cites showed stimulation of Wnt signaling accompanied by regrowth of structurally normal retinal vessels alongside suppression of pathological vessel formation. These findings supported the IND application that the FDA has now cleared, allowing the DUET Phase 1b/2a study to proceed. The trial includes an open-label single-ascending-dose phase in both treatment-naive and previously treated patients, followed by a randomized, double-masked dose-expansion phase comparing two dose levels of SZN-8141 against Vabysmo in approximately 60 treatment-naive participants over three monthly doses with four months of follow-up.
First patient dosing is expected in Q4 2026, with initial data anticipated in the second half of 2027. The IND clearance also triggers a milestone payment that closes a $95.1 million private placement, securing funding for SZN-8141 and companion program SZN-8143.
Important caveats apply: all efficacy signals to date are preclinical, and Phase 1b/2a trials are primarily designed to assess safety and tolerability, not to establish definitive clinical benefit. Readers should await peer-reviewed trial results before drawing conclusions about therapeutic impact.
Key Findings
- SZN-8141 is first-in-class: it both activates Wnt/Frizzled 4 and blocks VEGF in a single antibody for diabetic eye disease.
- Preclinical data showed regrowth of normal retinal vessels alongside suppression of abnormal vessel formation.
- DUET trial will compare two SZN-8141 doses against approved drug Vabysmo in ~60 treatment-naive patients.
- First patient dosing expected Q4 2026; initial efficacy and safety data anticipated second half of 2027.
- IND clearance triggers $95.1 million funding milestone, supporting continued development of SZN-8141 and SZN-8143.
Methodology
This is an industry news report based on a corporate press release announcing IND clearance and trial initiation. No peer-reviewed preclinical data are cited directly; efficacy claims rest solely on company-reported preclinical findings. Evidence quality is early-stage and requires independent verification.
Study Limitations
All efficacy data cited are preclinical; human safety and efficacy remain unproven. The DUET trial is sized primarily for safety signal detection, not definitive efficacy. Financial interests of the issuing company may influence how preclinical results are framed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: